Incorporating Portfolio Uncertainty in Decision Rules for Healthcare Resource Allocation.
cost-effectiveness analysis
opportunity costs
resource allocation
risk aversion
uncertainty
Journal
Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525
Informations de publication
Date de publication:
14 Mar 2021
14 Mar 2021
Historique:
received:
27
01
2021
revised:
07
03
2021
accepted:
11
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Cost-effectiveness analysis is widely adopted as a means to inform policy and decision makers in setting priorities for healthcare resource allocation. In resource-constrained settings, decision makers are confronted with healthcare resource reallocation decisions, e.g., moving funds from one or more existing healthcare programs to fund new healthcare programs. The decision-making plane (DMP) has been developed as a means to graphically present the results of reallocating available healthcare resources when healthcare program costs and effects are uncertain. Mapping a value function over the DMP allows the analyst to value all possible combinations of net costs and net effects that may result from reallocating available healthcare resources under conditions of uncertainty. In this paper, we extend this approach to include a change in portfolio risk, stemming from a change in the portfolios of funded healthcare programs, as an additional source of uncertainty, and demonstrate how this can be incorporated into the value function over net costs and net effects for a risk-averse decision maker. The methodology presented in this paper is of particular interest to decision makers who are risk averse, as it will help to better incorporate their preferences in the process of deciding how to best allocate scarce healthcare resources.
Identifiants
pubmed: 33799361
pii: healthcare9030325
doi: 10.3390/healthcare9030325
pmc: PMC8000383
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Pharmacoeconomics. 2021 Feb;39(2):161-169
pubmed: 33128734
Health Econ. 2008 Jan;17(1):99-107
pubmed: 17497751
Med Decis Making. 2007 Mar-Apr;27(2):101-11
pubmed: 17409361
Appl Health Econ Health Policy. 2002;1(3):135-9
pubmed: 14619264
Pharmacoeconomics. 2006;24(11):1121-31
pubmed: 17067196
CMAJ. 1993 Mar 15;148(6):913-7
pubmed: 8448705
Soc Sci Med. 2006 May;62(9):2091-100
pubmed: 16325975
N Engl J Med. 1977 Mar 31;296(13):716-21
pubmed: 402576
Value Health. 2019 Jul;22(7):785-791
pubmed: 31277825
Value Health. 2019 Aug;22(8):898-905
pubmed: 31426931
Expert Rev Pharmacoecon Outcomes Res. 2005 Dec;5(6):661-5
pubmed: 19807606
Value Health. 2004 Sep-Oct;7(5):518-28
pubmed: 15367247
Vaccine. 2019 Jan 7;37(2):226-234
pubmed: 30527660
Health Econ. 2005 May;14(5):457-70
pubmed: 15386661
AIDS. 1999 Jun 18;13(9):1115-22
pubmed: 10397543
Soc Sci Med. 2003 Dec;57(11):2207-15
pubmed: 14512250
J Eval Clin Pract. 1999 Aug;5(3):283-95
pubmed: 10461580
J Health Econ. 1992 Oct;11(3):279-96
pubmed: 10122540
Pharmacoeconomics. 2019 Mar;37(3):407-417
pubmed: 30499065
Health Econ. 2005 Jul;14(7):655-67
pubmed: 15678518
Health Econ. 2002 Jan;11(1):23-31
pubmed: 11788979
Health Econ. 2001 Oct;10(7):675-80
pubmed: 11747050
Soc Sci Med. 2020 Feb;246:112775
pubmed: 31923838
Health Econ. 2013 Nov;22(11):1287-94
pubmed: 23280702
J Health Econ. 1983 Aug;2(2):161-5
pubmed: 10310324
Med Care. 2000 May;38(5):460-8
pubmed: 10800973